CN115708418A - SARS-CoV-2假病毒及其检测样品中和SARS-CoV-2能力的方法 - Google Patents

SARS-CoV-2假病毒及其检测样品中和SARS-CoV-2能力的方法 Download PDF

Info

Publication number
CN115708418A
CN115708418A CN202180038153.3A CN202180038153A CN115708418A CN 115708418 A CN115708418 A CN 115708418A CN 202180038153 A CN202180038153 A CN 202180038153A CN 115708418 A CN115708418 A CN 115708418A
Authority
CN
China
Prior art keywords
cov
sars
pseudovirus
variant
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038153.3A
Other languages
English (en)
Inventor
贾文双
汪伟明
李恋曲
张娴
杨梦丽
刘传鑫
殷刘松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Vigorous Biotechnology Co ltd
Original Assignee
Nanjing Vigorous Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Vigorous Biotechnology Co ltd filed Critical Nanjing Vigorous Biotechnology Co ltd
Priority to CN202310524561.0A priority Critical patent/CN116904405A/zh
Priority to CN202310528005.0A priority patent/CN116622641A/zh
Publication of CN115708418A publication Critical patent/CN115708418A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明属于生物技术领域，具体涉及SARS‑CoV‑2假病毒及其检测样品中和SARS‑CoV‑2能力的方法。本发明提供了一种检测样品中和SARS‑CoV‑2病毒或其突变体的能力的方法，包括如下步骤：(1)将SARS‑CoV‑2假病毒或其变体与所述样品接触，(2)将所述假病毒与样品的混合物与ACE2过表达的细胞系接触培养，和(3)通过检测所述细胞系表达报告基因的情况确定所述样品是否具有中和所述SARS‑CoV‑2病毒或其突变体的能力。

Description

PCT国内申请，说明书已公开。

Claims (37)

  1. PCT国内申请，权利要求书已公开。
CN202180038153.3A 2020-05-28 2021-05-28 SARS-CoV-2假病毒及其检测样品中和SARS-CoV-2能力的方法 Pending CN115708418A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310524561.0A CN116904405A (zh) 2020-05-28 2021-05-28 SARS-CoV-2假病毒及其制备方法和应用
CN202310528005.0A CN116622641A (zh) 2020-05-28 2021-05-28 Ace2和tmprss2双过表达细胞系及其制备方法和应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020104705416 2020-05-28
CN202010470541 2020-05-28
PCT/CN2021/096593 WO2021239086A1 (zh) 2020-05-28 2021-05-28 SARS-CoV-2假病毒及其检测样品中和SARS-CoV-2能力的方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202310524561.0A Division CN116904405A (zh) 2020-05-28 2021-05-28 SARS-CoV-2假病毒及其制备方法和应用
CN202310528005.0A Division CN116622641A (zh) 2020-05-28 2021-05-28 Ace2和tmprss2双过表达细胞系及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115708418A true CN115708418A (zh) 2023-02-21

Family

ID=78745633

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310528005.0A Pending CN116622641A (zh) 2020-05-28 2021-05-28 Ace2和tmprss2双过表达细胞系及其制备方法和应用
CN202180038153.3A Pending CN115708418A (zh) 2020-05-28 2021-05-28 SARS-CoV-2假病毒及其检测样品中和SARS-CoV-2能力的方法
CN202310524561.0A Pending CN116904405A (zh) 2020-05-28 2021-05-28 SARS-CoV-2假病毒及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310528005.0A Pending CN116622641A (zh) 2020-05-28 2021-05-28 Ace2和tmprss2双过表达细胞系及其制备方法和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310524561.0A Pending CN116904405A (zh) 2020-05-28 2021-05-28 SARS-CoV-2假病毒及其制备方法和应用

Country Status (2)

Country Link
CN (3) CN116622641A (zh)
WO (1) WO2021239086A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114369141B (zh) * 2021-12-06 2023-09-01 浙江大学 一种靶向结合ace2蛋白的ace2靶向肽及其用途
CN114736930A (zh) * 2022-04-30 2022-07-12 南京医科大学 一种病毒蛋白逃逸中和抗体的筛选方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028497A2 (en) * 2003-09-15 2005-03-31 The Brigham And Women's Hospital Inc. Receptor binding peptides derived from the sars s protein
US20050249739A1 (en) * 2003-11-25 2005-11-10 Wayne Marasco Antibodies against SARS-CoV and methods of use thereof
WO2009036063A1 (en) * 2007-09-11 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudotyped retroviral vectors and methods of making and using them
CN105177043A (zh) * 2015-09-17 2015-12-23 杭州庆正鸿科技有限公司 一种h7n9假病毒的制备方法及该h7n9假病毒的应用
CN105866260A (zh) * 2016-03-21 2016-08-17 中国药科大学 一种筛选血管紧张素转化酶抑制剂的新方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028497A2 (en) * 2003-09-15 2005-03-31 The Brigham And Women's Hospital Inc. Receptor binding peptides derived from the sars s protein
US20050249739A1 (en) * 2003-11-25 2005-11-10 Wayne Marasco Antibodies against SARS-CoV and methods of use thereof
WO2009036063A1 (en) * 2007-09-11 2009-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudotyped retroviral vectors and methods of making and using them
CN105177043A (zh) * 2015-09-17 2015-12-23 杭州庆正鸿科技有限公司 一种h7n9假病毒的制备方法及该h7n9假病毒的应用
CN105866260A (zh) * 2016-03-21 2016-08-17 中国药科大学 一种筛选血管紧张素转化酶抑制剂的新方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATHARINE H. D. CRAWFORD等: "Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays", 《VIRUSES》, vol. 12, no. 513, pages 2 - 10 *
MARKUS HOFFMANN等: "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor", 《CELL》, vol. 181, pages 271 - 280 *

Also Published As

Publication number Publication date
CN116904405A (zh) 2023-10-20
WO2021239086A1 (zh) 2021-12-02
CN116622641A (zh) 2023-08-22

Similar Documents

Publication Publication Date Title
WO2021254327A1 (zh) 一种包膜替换型病毒载体疫苗及其构建方法
TWI297040B (en) Recombinant baculovirus and virus-like particle
Teoh et al. The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis
CN112386684B (zh) 一种covid-19疫苗及其制备方法和应用
CN112321688B (zh) 稳定的冠状病毒重组蛋白二聚体及其表达载体
CN112724209B (zh) 可形成纳米颗粒的冠状病毒重组蛋白及其载体和应用
Lévy et al. Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells
CN111560076A (zh) 一种嵌合抗原受体免疫细胞及其制备方法和应用
Luo et al. Contribution of N-linked glycans on HSV-2 gB to cell–cell fusion and viral entry
Emerson et al. Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein
EP2069393A2 (en) Avian influenza vaccine
CN115708418A (zh) SARS-CoV-2假病毒及其检测样品中和SARS-CoV-2能力的方法
Denner Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study
Qiu et al. Proteasomal degradation of human SERINC4: a potent host anti-HIV-1 factor that is antagonized by nef
DK1981904T3 (en) Peptide domain from the enclosure of a HERV-W virus, which is required for reaction with a hASCT receptor
González et al. Palmitoylation of the feline immunodeficiency virus envelope glycoprotein and its effect on fusion activity and envelope incorporation into virions
CN113621598A (zh) 钙蛋白酶-1在抵抗猪流行性腹泻病毒感染中的应用
US20240058380A1 (en) Corona virus-specific t cell receptor fusion constructs, vectors encoding the same, t cells comprising the same and uses thereof
Lamb et al. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope
US20230331815A1 (en) Methods and compositions for treating viral infection
US20240181042A1 (en) Sars-cov-2 vaccine composition and use thereof
WO2005063798A1 (en) Identification of two linear epitopes on ebola or marburg virus glycoproteins critical for infection
EP3104884B1 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection
CN115925992A (zh) 一种SARS-CoV-2四聚体RBD融合蛋白及其应用
CN117186207A (zh) 一种猪德尔塔冠状病毒感染的特异性宿主因子及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230221

WD01 Invention patent application deemed withdrawn after publication